cryopreserved ex vivo expanded polyclonal cd4+cd127lo/-cd25+ t regulatory cells
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 11, 2021 (NCT05027815)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- regulatory t cellsSupplementation
regulatory t cells supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05027815 | Phase 1 | Oct 11, 2021 | Immune Tolerance Network, National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco, Yale University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immune Tolerance Network | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1